Ketek's new labeling approved by FDA

Share this article:
Ketek (telithromycin), Sanofi-Aventis' antibiotic, has had new labeling approved by the FDA, including a bolded warning and additional information on liver toxicity and failure, as well as revised recommendations for use in patients with myasthenia gravis. The agency says Ketek's benefits outweigh its potential risks when used according to the labeling.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions